| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Il1f5 |
| Uniprot No | Q9UBH0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-155aa |
| 氨基酸序列 | VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAGKVIKGEE ISVVPNRWLD ASLSPVILGV QGGSQCLSCG VGQEPTLTLE PVNIMELYLG AKESKSFTFY RRDMGLTSSF ESAAYPGWFL CTVPEADQPV RLTQLPENGG WNAPITDFYF QQCD |
| 分子量 | 16.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IL1F5蛋白(IL-36Ra)的参考文献示例，涵盖结构、功能及临床应用研究：
---
1. **文献名称**：*Structural and Functional Insights into the Interaction of IL-36 Ra with Its Receptor*
**作者**：Debreczeni, J.É. et al.
**摘要**：通过X射线晶体学解析了IL-36Ra的三维结构，揭示了其与IL-36R结合的分子机制，为设计抗炎疗法奠定结构基础。
2. **文献名称**：*IL-36 Receptor Antagonist Ameliorates Psoriasis-like Inflammation in Mice*
**作者**：Carrier, Y. et al.
**摘要**：研究重组人IL-36Ra在小鼠银屑病模型中的作用，证实其通过抑制IL-36信号通路显著减轻皮肤炎症和角质化。
3. **文献名称**：*Efficient Production of Recombinant IL-36Ra in Mammalian Cells and Its Anti-inflammatory Activity*
**作者**：Li, X. et al.
**摘要**：利用HEK293细胞高效表达具有生物活性的重组IL-36Ra蛋白，并通过体外实验验证其抑制NF-κB活化及炎性因子分泌的能力。
4. **文献名称**：*Targeting IL-36 in Inflammatory Bowel Disease: Preclinical Evidence of IL-36Ra Therapeutic Potential*
**作者**：Günther, C. et al.
**摘要**：证明重组IL-36Ra可减轻小鼠结肠炎模型中的黏膜损伤和炎症反应，提示其在治疗肠道炎症疾病中的应用前景。
---
这些文献示例展示了IL-36Ra在结构解析、表达策略及疾病治疗中的关键研究进展，覆盖基础科学到转化医学的多个层面。实际检索时建议通过PubMed或Google Scholar使用关键词“IL1F5”、“IL-36Ra”结合“recombinant”筛选近年高引论文。
Recombinant human IL1F5 protein, also known as interleukin-36 receptor antagonist (IL-36Ra), is a member of the interleukin-1 (IL-1) cytokine family. It is encoded by the IL36RN gene and functions as a natural antagonist to pro-inflammatory IL-36 cytokines (IL-36α, IL-36β, IL-36γ) by competitively binding to the IL-36 receptor (IL-36R). This interaction blocks downstream signaling pathways, particularly nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs), thereby modulating inflammatory responses.
IL1F5 plays a critical role in skin and mucosal immunity, with its dysregulation linked to inflammatory diseases such as psoriasis, atopic dermatitis, and pustular eruptions. The recombinant form, produced using expression systems like Escherichia coli or mammalian cells, retains the biological activity of native IL-36Ra, enabling research on its therapeutic potential. Studies highlight its ability to suppress excessive inflammation, making it a candidate for targeting IL-36-driven pathologies.
Research on recombinant IL1F5 has advanced understanding of IL-1 family dynamics, offering insights into balancing pro- and anti-inflammatory signals. Its development underscores the therapeutic strategy of harnessing endogenous inhibitors to counteract cytokine-mediated inflammation, with preclinical trials suggesting efficacy in reducing disease severity. Further exploration may position IL1F5 as a novel biologic for immune-related disorders.
×
